Andrew Daly

3.5k total citations
76 papers, 1.7k citations indexed

About

Andrew Daly is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Andrew Daly has authored 76 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 18 papers in Immunology and 17 papers in Oncology. Recurrent topics in Andrew Daly's work include Hematopoietic Stem Cell Transplantation (42 papers), Acute Myeloid Leukemia Research (17 papers) and Acute Lymphoblastic Leukemia research (16 papers). Andrew Daly is often cited by papers focused on Hematopoietic Stem Cell Transplantation (42 papers), Acute Myeloid Leukemia Research (17 papers) and Acute Lymphoblastic Leukemia research (16 papers). Andrew Daly collaborates with scholars based in Canada, United States and Australia. Andrew Daly's co-authors include Jan Storek, Douglas A. Stewart, Jeffrey H. Lipton, Thomas Kiss, Hans A. Messner, Faisal Khan, Wanda Hasegawa, Peter Duggan, Edmund K. Waller and Partow Kebriaei and has published in prestigious journals such as Blood, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Andrew Daly

74 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Daly Canada	24	950	413	384	364	349	76	1.7k
Fen Huang China	26	1.2k 1.2×	431 1.0×	551 1.4×	566 1.6×	270 0.8×	155	2.2k
Carmem Bonfim Brazil	24	925 1.0×	325 0.8×	248 0.6×	454 1.2×	222 0.6×	146	1.9k
Sujith Samarasinghe United Kingdom	21	868 0.9×	285 0.7×	320 0.8×	550 1.5×	224 0.6×	55	1.8k
Pietro Merli Italy	26	909 1.0×	601 1.5×	215 0.6×	442 1.2×	176 0.5×	109	1.8k
Ho Joon Im South Korea	23	741 0.8×	373 0.9×	320 0.8×	313 0.9×	191 0.5×	151	1.6k
Shelly L. Carter United States	20	1.6k 1.7×	644 1.6×	441 1.1×	639 1.8×	572 1.6×	30	2.3k
Daria Pagliara Italy	21	678 0.7×	685 1.7×	352 0.9×	638 1.8×	182 0.5×	65	1.7k
Jean‐Michel Boiron France	21	1.0k 1.1×	336 0.8×	489 1.3×	313 0.9×	110 0.3×	60	1.7k
Ildefonso Espigado Spain	21	452 0.5×	206 0.5×	324 0.8×	301 0.8×	380 1.1×	78	1.3k
Xiaoyu Chai United States	23	945 1.0×	296 0.7×	198 0.5×	468 1.3×	84 0.2×	51	1.8k

Countries citing papers authored by Andrew Daly

Since Specialization

Citations

This map shows the geographic impact of Andrew Daly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Daly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Daly more than expected).

Fields of papers citing papers by Andrew Daly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Daly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Daly. The network helps show where Andrew Daly may publish in the future.

Co-authorship network of co-authors of Andrew Daly

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Daly. A scholar is included among the top collaborators of Andrew Daly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Daly. Andrew Daly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abedin, Tasnima, S. Ali Naqvi, Hua Shen, et al.. (2022). Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation. Blood Advances. 6(3). 767–773. 7 indexed citations

Williamson, Tyler, Kareem Jamani, Ahsan Chaudhry, et al.. (2021). Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(1). 53.e1–53.e10. 15 indexed citations

Williamson, Tyler, Nicole L. Prokopishyn, Poonam Dharmani‐Khan, et al.. (2020). Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low‐dose total body irradiation, and rabbit antithymocyte globulin. Clinical Transplantation. 34(9). e14018–e14018. 11 indexed citations

Bhella, Sita, Navneet S. Majhail, Luciano J. Costa, et al.. (2018). Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 24(5). 909–913. 31 indexed citations

Williamson, Tyler, Raymond Tellier, Ahsan Chaudhry, et al.. (2018). Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder. Cytotherapy. 20(5). 706–714. 20 indexed citations

Williamson, Tyler, Raymond Tellier, Ahsan Chaudhry, et al.. (2017). Risk factors for post‐transplant lymphoproliferative disorder after Thymoglobulin‐conditioned hematopoietic cell transplantation. Clinical Transplantation. 32(1). 21 indexed citations

Davidson, Marta, Douglas A. Stewart, Peter Duggan, Andrew Daly, & Mona Shafey. (2017). Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis. Blood. 130. 4534–4534. 1 indexed citations

Faridi, Rehan M., Poonam Dharmani‐Khan, Victor Lewis, et al.. (2016). Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation. PLoS ONE. 11(6). e0158242–e0158242. 23 indexed citations

Lim, Andrew, Jan Storek, Marnie Collins, et al.. (2015). Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis. Bone Marrow Transplantation. 50(4). 566–572. 4 indexed citations

10.

Podgorny, Peter, Yiping Liu, Poonam Dharmani‐Khan, et al.. (2015). Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(1). 37–46. 16 indexed citations

11.

Russell, James A., Tyler Williamson, M. Ahsan Chaudhry, et al.. (2013). Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 19(9). 1381–1386. 27 indexed citations

12.

Ugarte-Torres, Alejandra, Mette Hoegh-Petersen, Peter Podgorny, et al.. (2012). IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. Bone Marrow Transplantation. 48(5). 722–728. 22 indexed citations

13.

Hoegh-Petersen, Mette, Yiping Liu, Peter Podgorny, et al.. (2012). Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. 14(10). 1258–1275. 126 indexed citations

14.

Ng, Ella S.M., M. Ahsan Chaudhry, Judy Wu, et al.. (2011). Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing. Biology of Blood and Marrow Transplantation. 18(2). 295–301. 31 indexed citations

15.

Alimohamed, Nimira, Andrew Daly, Carolyn Owen, Peter Duggan, & Douglas A. Stewart. (2011). Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leukemia & lymphoma. 53(5). 862–867. 45 indexed citations

16.

Hoegh-Petersen, Mette, Dawn Goodyear, Michelle Geddes, et al.. (2010). High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplantation. 46(8). 1104–1112. 32 indexed citations

17.

Silverman, Michael, Donna L. Reynolds, Peter A. Kavsak, et al.. (2007). Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis. Clinical Biochemistry. 40(12). 913–915. 10 indexed citations

18.

Daly, Andrew, Suzanne Kamel‐Reid, Jeffrey H. Lipton, et al.. (2004). Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. Leukemia Research. 28(10). 1107–1111. 13 indexed citations

19.

Gupta, Vikas, Joseph Brandwein, Mark D. Minden, et al.. (2003). The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplantation. 33(4). 397–404. 33 indexed citations

20.

Daly, Andrew, Wanda Hasegawa, Jeffrey H. Lipton, Hans A. Messner, & Thomas Kiss. (2002). Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfusion and Apheresis Science. 27(1). 3–12. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact